Flag of the European Union EU Clinical Trials Register Help

Clinical trials for II

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11,926 result(s) found for: II. Displaying page 95 of 597.
    «« First « Previous 91  92  93  94  95  96  97  98  99  Next» Last»»
    EudraCT Number: 2014-002950-38 Sponsor Protocol Number: MK-3475-051 Start Date*: 2014-11-10
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
    Medical condition: Treatment of advanced melanoma or advanced, relapsed or refractory PD-L1 positive malignant solid tumor or lymphoma in children from 6 months to less than 18 years old.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004294-14 Sponsor Protocol Number: RPC01-3203 Start Date*: 2018-03-06
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) CZ (Trial now transitioned) LT (Completed) FR (Trial now transitioned) SI (Completed) AT (Completed) BG (Trial now transitioned) DE (Trial now transitioned) GR (Completed) ES (Ongoing) SE (Prematurely Ended) NL (Completed) NO (Completed) PL (Trial now transitioned) BE (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Completed) DK (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002112-41 Sponsor Protocol Number: 2016-05-04 Start Date*: 2016-07-16
    Sponsor Name:Region Östergötland
    Full Title: Can Insuline improve the healing of dental implants?
    Medical condition: Missing teeth
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003060-37 Sponsor Protocol Number: ANZUP1302 Start Date*: 2017-04-05
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: UK P3BEP - A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
    Medical condition: International germ cell classification catergory (IGCCC) intermediate or poor-risk metastatic germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068971 Germ cell cancer metastatic PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-005347-14 Sponsor Protocol Number: H2020/PHRC-N/2014/GB-01 Start Date*: 2016-08-25
    Sponsor Name:CHU DE NIMES
    Full Title: Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, pla...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003523-36 Sponsor Protocol Number: 2005B016 Start Date*: 2007-07-30
    Sponsor Name:Netherlands Heart Foundation
    Full Title: Magnesium in Aneurysmal Subarachnoid Haemorrhage
    Medical condition: Aneurysmal subarachnoid haemorrhage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-009889-13 Sponsor Protocol Number: CACZ885I2202 Start Date*: 2009-08-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Doub...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022170-14 Sponsor Protocol Number: DN10007 Start Date*: 2010-12-16
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Open-label, ascending-dose, Phase II study to determine the minimum effective dose of APD421 (intravenous amisulpride) in the prevention of cisplatin-induced nausea and vomiting
    Medical condition: Cisplatin-induced nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-021447-41 Sponsor Protocol Number: SAPROCAN2011 Start Date*: 2011-05-12
    Sponsor Name:NHS Greater Glasgow Health Board [...]
    1. NHS Greater Glasgow Health Board
    2. Glasgow University
    Full Title: SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group
    Medical condition: Metastatic, castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016050-41 Sponsor Protocol Number: E7080-701 Start Date*: 2010-07-29
    Sponsor Name:Eisai Inc.
    Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Plati...
    Medical condition: Platinum-Sensitive Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004647-37 Sponsor Protocol Number: G0373 Start Date*: 2006-11-06
    Sponsor Name:Bangor University
    Full Title: Folate Augmentation of Treatment – Evaluation of Depression: a randomised controlled trial
    Medical condition: Individuals with moderate to severe depression according to ICD-10 criteria.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005538-20 Sponsor Protocol Number: BA2011/15/02 Start Date*: 2012-05-15
    Sponsor Name:BioAlliance Pharma
    Full Title: SAFETY AND EFFICACY OF INTRAMUSCULAR ELECTROTRANSFER OF PLASMID AMEP IN PATIENTS SUFFERING FROM ADVANCED OR METASTATIC MELANOMA: AN OPEN-LABEL PHASE I/II CLINICAL TRIAL THE AIMM STUDY (AMEP IN MET...
    Medical condition: Treatment of patients suffering from advanced or metastatic melanoma (stages III, IV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-005134-38 Sponsor Protocol Number: ABRAMYO Start Date*: 2014-03-19
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI - IRE
    Full Title: Phase I-II study of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) in combination with liposomal encapsulated doxorubicin (LDox) in patients with HER2 negative metastatic breas...
    Medical condition: Her2 negative metastatic breast cancer first line
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003689-28 Sponsor Protocol Number: BrEPEM-LH-22017 Start Date*: 2018-04-05
    Sponsor Name:GELTAMO (Grupo Español de Linfomas y trasplante autólogo de médula osea)
    Full Title: A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Ly...
    Medical condition: Older Patients with Untreated Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004335-36 Sponsor Protocol Number: ANAVEX2-73-PDD-001 Start Date*: 2018-07-04
    Sponsor Name:Anavex Life Sciences Corp.
    Full Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients.
    Medical condition: Cognition in Parkinson’s Disease with dementia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001707-16 Sponsor Protocol Number: TOCICOVID Start Date*: 2020-06-25
    Sponsor Name:IIS BIODONOSTIA
    Full Title: PHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEU...
    Medical condition: bilateral SARS-CoV-2 pneumonia with poor clinical course
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004288-31 Sponsor Protocol Number: IMRT AMI Start Date*: 2005-01-28
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Phase II parallel studies on the use of 3D-radiotherapy plus Amifostine or IMRT to evaluate xerostomia reduction in patients with head and neck cancer treated in definitve or postoperative setting.
    Medical condition: subcutaneous amiphostine with 3D-radiotherapy to reduce xerostomia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-002860-43 Sponsor Protocol Number: SAKK 36/03 Start Date*: 2005-03-31
    Sponsor Name:SIAK
    Full Title: Master protocol for mantle cell lymphoma A multicenter phase II trial testing Gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma...
    Medical condition: patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025323 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000804-10 Sponsor Protocol Number: 6208 Start Date*: 2008-03-31
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Valsartan 160 mg and hydrochlorothiazide 25 mg in subject suffering from arterial hypertension stage 1 or high normal with organ damage
    Medical condition: Arterial Hypertension with organ damage
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004682-11 Sponsor Protocol Number: AUTO3-DB1 Start Date*: 2017-07-19
    Sponsor Name:Autolus Limited
    Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 with Anti PD-1 Antibody in Patients wi...
    Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL) and large B cell lymphoma subsets
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    20.0 100000004851 10036711 Primary mediastinal large B-cell lymphomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036710 Primary mediastinal large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 91  92  93  94  95  96  97  98  99  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 23:22:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA